ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 661,40
-0,36%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Annovis Bio Inc (ANVS)

  7. Annovis Bio Inc (ANVS) Actualités

ANVS

Annovis Bio (ANVS)

Annovis Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:ANVS
DateHeureSourceTitreSymboleSociété
01/04/202414h00GlobeNewswire Inc.Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in HumansAMEX:ANVSAnnovis Bio Inc
20/03/202412h30GlobeNewswire Inc.Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s DiseaseAMEX:ANVSAnnovis Bio Inc
27/02/202414h00GlobeNewswire Inc.Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024AMEX:ANVSAnnovis Bio Inc
14/02/202413h30GlobeNewswire Inc.Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s DiseaseAMEX:ANVSAnnovis Bio Inc
30/01/202414h00GlobeNewswire Inc.Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s PortfolioAMEX:ANVSAnnovis Bio Inc
24/01/202414h00GlobeNewswire Inc.Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data AnnouncementAMEX:ANVSAnnovis Bio Inc
11/12/202319h00GlobeNewswire Inc.Annovis Bio to Participate in the 139th Yale CEO SummitAMEX:ANVSAnnovis Bio Inc
05/12/202313h30GlobeNewswire Inc.Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s DiseaseAMEX:ANVSAnnovis Bio Inc
01/12/202313h30GlobeNewswire Inc.Annovis Bio Appoints Andrew Walsh as Vice President FinanceAMEX:ANVSAnnovis Bio Inc
27/11/202313h30GlobeNewswire Inc.Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original ProjectionsAMEX:ANVSAnnovis Bio Inc
08/11/202323h00GlobeNewswire Inc.Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateAMEX:ANVSAnnovis Bio Inc
12/10/202314h02GlobeNewswire Inc.Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s StudyAMEX:ANVSAnnovis Bio Inc
16/06/202322h19Edgar (US Regulatory)Current Report Filing (8-k)AMEX:ANVSAnnovis Bio Inc
10/05/202322h35Edgar (US Regulatory)Quarterly Report (10-q)AMEX:ANVSAnnovis Bio Inc
28/04/202314h01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:ANVSAnnovis Bio Inc
26/04/202322h34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:ANVSAnnovis Bio Inc
25/04/202312h01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)AMEX:ANVSAnnovis Bio Inc
18/04/202222h14Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)AMEX:ANVSAnnovis Bio Inc
02/03/202222h18Edgar (US Regulatory)Annual Report (10-k)AMEX:ANVSAnnovis Bio Inc
 Showing the most relevant articles for your search:AMEX:ANVS

Dernières Valeurs Consultées

EU
DG
Vinci
EU
EN
Bouygues
EU
BEL20
Bel 20
EU
CAP
Capgemini
NYSE
MRK
Merck
EU
SGO
Cie de SaintGobain
EU
BN
Danone
EU
RNO
Renault
NYSE
MCD
McDonalds
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
SPI
SP500
S&P 500
EU
MC
Lvmh Moet Hennessy Louis...
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés